Elevance Health (NYSE:ELV) Given New $424.00 Price Target at Sanford C. Bernstein

Elevance Health (NYSE:ELV) had its price target hoisted by Sanford C. Bernstein from $384.00 to $424.00 in a research note released on Friday,MarketScreener reports. The brokerage currently has an outperform rating on the stock.

ELV has been the subject of a number of other reports. Robert W. Baird upped their price objective on shares of Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a research note on Thursday. Guggenheim upped their price objective on shares of Elevance Health from $396.00 to $399.00 and gave the company a “buy” rating in a research note on Friday. JPMorgan Chase & Co. upped their price objective on shares of Elevance Health from $394.00 to $397.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Wall Street Zen lowered shares of Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Finally, Evercore increased their price target on shares of Elevance Health from $345.00 to $360.00 in a research report on Thursday. Eleven analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Elevance Health has an average rating of “Hold” and an average target price of $380.42.

Elevance Health Price Performance

NYSE ELV opened at $344.64 on Friday. The stock has a market capitalization of $74.84 billion, a P/E ratio of 14.66, a P/E/G ratio of 1.84 and a beta of 0.49. Elevance Health has a 1 year low of $273.71 and a 1 year high of $427.54. The business’s fifty day moving average is $308.96 and its two-hundred day moving average is $331.62. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.48.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. During the same quarter in the prior year, the company earned $11.97 earnings per share. The firm’s revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, research analysts forecast that Elevance Health will post 26.79 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s payout ratio is currently 27.39%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Physician Wealth Advisors Inc. raised its holdings in shares of Elevance Health by 331.6% in the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after buying an additional 63 shares during the last quarter. Rossby Financial LCC increased its position in Elevance Health by 110.0% in the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after purchasing an additional 44 shares during the period. Activest Wealth Management increased its position in Elevance Health by 66.7% in the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 34 shares during the period. Kemnay Advisory Services Inc. acquired a new stake in Elevance Health in the fourth quarter worth about $31,000. Finally, J.Safra Asset Management Corp acquired a new stake in Elevance Health in the fourth quarter worth about $32,000. 89.24% of the stock is owned by institutional investors.

Key Headlines Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 beat and upgraded outlook — ELV reported strong Q1 results (EPS $12.58 vs. estimates) and raised its 2026 adjusted EPS outlook to at least $26.75 while targeting ~12% EPS growth in 2027, which supports earnings upside and margin improvement. Elevance raises 2026 outlook
• Positive Sentiment: Large analyst upgrade — Sanford C. Bernstein raised its price target to $424 and kept an “outperform” rating, implying ~23% upside; a high-conviction bullish call that can attract demand. Bernstein raises PT to $424
• Positive Sentiment: Barclays reiteration of Buy — Barclays stuck with a Buy rating, signaling institutional confidence that can provide support for the shares. Barclays sticks to Buy
• Positive Sentiment: Operational tailwinds noted — Management highlighted medical cost controls and AI-driven margin expansion, and major outlets reported the company raised its annual profit forecast on those controls, reinforcing the positive earnings message. Profit forecast raised on cost controls
• Neutral Sentiment: Mixed analyst PT lifts with conservative ratings — Several firms nudged up targets but kept neutral/hold stances (Goldman to $370 neutral; Deutsche Bank to $363 hold; Evercore to $360 in-line). These raise reference prices but signal measured optimism. Goldman raises PT to $370
• Neutral Sentiment: Jefferies update — Jefferies revised its forecasts after a deeper look at exchange-segment dynamics and trimmed its PT slightly; this is an analyst reshuffle rather than a directional shock. Jefferies updates forecasts
• Negative Sentiment: Investor litigation probe — Law firm Kirby McInerney has opened an investigation into potential securities claims involving Elevance and/or its senior management; legal scrutiny can pressure the stock and raise uncertainty. Kirby McInerney investor alert
• Negative Sentiment: Some broker nuance implies limited near-term upside — Robert W. Baird’s update leaves a neutral stance with a lower relative target vs. some peers, noting limited immediate upside which can cap buying interest. Baird adjusts PT

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.